European pharma group wants to create PRV-like system to spur antibiotics R&D

New research funded by a European pharma industry group is looking to reinvigorate antimicrobial R&D with a system that’s similar to the priority review voucher systems in the US, which spurs new research in rare pediatric diseases, rare tropical diseases and medical countermeasures.